Shenzhen-based point-of-care testing (POCT) specialist Corestar Biotechnology Co., Ltd has raised “tens of millions” of renminbi in a Series A financing round led by IDG Capital. The proceeds will be used for research and development (R&D) laboratory construction, new product pipeline expansion, and team expansion.
Company Background
Founded in 2017, Corestar Bio has developed the world’s smallest next-generation POCT system, with over 20 patents. Its first product has received marketing approval, enabling the continuity of testing, diagnosis, and treatment.-Fineline Info & Tech
